TICKERNERD
Menu
LSTALSTAHealthcare · Biotechnology

LSTA Stock Forecast: Lisata Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$1.70
−2.30% on the day

The 2 Wall Street analysts covering Lisata Therapeutics, Inc. hold a median 12-month price target of $4 — +135.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 19 Sept 2026 — in the upper half.

Market cap
$18.4M
Ticker Nerd rank
56 / 100
Median analyst target
$4.00
Analysts covering
2
Revenue$0.0−100.0% y/y
Operating income−$4.0M
Net income−$2.9M
Free cash flow−$2.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.3%
1M
+47.8%
YTD
−8.6%
1Y
−28.9%
From 52W high
−66.3%
From 52W low
+71.7%
$0.99
$5.04
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LSTA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lisata Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
56 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
90
Accruals
83
Growth
81
Volatility
72
Issuance
54
Momentum
43
Quality
33
Value
29
Revisions
26

Size (90): Smaller than most of the companies we track.

Revisions (26): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LSTA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LSTA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26LSTAHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
0 Buy2 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +135.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 May 2026HC Wainwright & Co.DowngradeNeutral—
21 Jan 2026Brookline CapitalDowngradeHold—
21 Aug 2025HC Wainwright & Co.ReiteratesBuy—
15 July 2025Brookline CapitalMaintainsBuy—
11 Dec 2024HC Wainwright & Co.ReiteratesBuy—
21 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Sept 2024HC Wainwright & Co.ReiteratesBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
19 July 2024HC Wainwright & Co.ReiteratesBuy—
10 July 2024HC Wainwright & Co.ReiteratesBuy—
14 June 2024HC Wainwright & Co.ReiteratesBuy—
21 May 2024HC Wainwright & Co.ReiteratesBuy—
26 Apr 2024HC Wainwright & Co.ReiteratesBuy—
25 Apr 2024HC Wainwright & Co.ReiteratesBuy—
1 Mar 2024HC Wainwright & Co.ReiteratesBuy—
4 Jan 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.ReiteratesBuy—
25 May 2023HC Wainwright & Co.ReiteratesBuy—
31 Mar 2023HC Wainwright & Co.ReiteratesBuy—
19 Oct 2022HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LSTA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LSTA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Lisata Therapeutics, Inc. returned −28.9% against +16.3% for the S&P 500, dividends included.

LSTA vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Oct 25Jan 26Apr 26Jul 26LSTAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LSTA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Lisata Therapeutics, Inc. (LSTA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.9×

Cheaper than 82% of US stocks

Price / sales
183.7×

Cheaper than 3% of US stocks

Price / book
1.9×

Cheaper than 46% of US stocks

EV / EBITDA
−0.3×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−16426.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−101.7%

Higher than 13% of US stocks

Return on assets
−56.7%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lisata Therapeutics, Inc. (LSTA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lisata Therapeutics, Inc. has a market value of $18.4M and an enterprise value of $4.6M.

  • Revenue in the twelve months to 30 June 2026: $100K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$14.6M, a −14621.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$12.3M.

  • Shares outstanding: 9.1M.

  • Trailing P/E: −0.9×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Lisata Therapeutics, Inc. employs 21 people — $5K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

LSTA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LSTALisata Therapeutics, Inc.$18.4M
56
PASGPassage Bio, Inc.$15.3M
43
CNSYCerenome, Inc.$15.4M
17
DAREDaré Bioscience, Inc.$15.2M
27
TPSTTempest Therapeutics, Inc.$15.5M
37
MBRXMoleculin Biotech, Inc.$15.1M
25
ICUSeastar Medical Holding Corp.$15.6M
21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lisata Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LSTA news & analysis

Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy

Benzinga · 17 Sept 2026positive

Lisata Therapeutics announced it has acquired clinical-stage biotechnology company Marea Therapeutics, alongside an oversubscribed $225 million private placement financing. The moves are aimed at bolstering its cardioendocrine pipeline strategy.

Why it matters — For LSTA watchers, the acquisition of Marea and the oversized financing signal an expansion of the company's cardioendocrine pipeline strategy.

Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement

Proactive Investors · 17 Sept 2026positive

Lisata Therapeutics has acquired Marea Therapeutics, a clinical-stage biotech focused on next-generation medicines for cardioendocrine diseases. The companies also entered into a private placement financing agreement expected to raise approximately $225 million in gross proceeds.

Why it matters — This acquisition expands Lisata's pipeline into cardioendocrine disease while the private placement provides substantial capital to fund its operations.

Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement

GlobeNewsWire · 17 Sept 2026positive

Lisata Therapeutics announced the acquisition of Marea Therapeutics and a $225 million concurrent private placement from leading life sciences and institutional investors. The combined company will focus on developing first-in-class next-generation medicines for cardioendocrine diseases, with Marea's late-stage candidates including MAR001/005 for severe hypertriglyceridemia and MAR002 for acromegaly, with funding projected to support operations into 2028.

Why it matters — For LSTA watchers, this acquisition expands the company into cardioendocrine disease therapies and brings a substantial capital injection that is projected to fund operations into 2028.

Lisata Therapeutics moves forward with legal action following Kuva merger termination

Proactive Investors · 4 Aug 2026neutral

Lisata Therapeutics announced it has filed a lawsuit in the Delaware Court of Chancery alleging Kuva Labs and Kuva Acquisition Corp breached the merger agreement dated March 6, 2026, following termination of the merger. Lisata said it is acting to protect stockholder interests and strengthen its financial position.

Why it matters — LSTA watchers would care because the company is taking legal action over the failed Kuva merger to protect stockholder interests amid its development of therapies for advanced solid tumors.

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

GlobeNewsWire · 4 Aug 2026negative

Lisata Therapeutics announced it has terminated its merger agreement with Kuva Labs Inc. and has filed a lawsuit seeking damages for the benefit of its stockholders.

Why it matters — A terminated merger and resulting litigation could impact Lisata's strategic direction and financial resources, introducing uncertainty for shareholders.

FAQ

Frequently asked questions about LSTA stock

What is the LSTA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Lisata Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LSTA stock a buy right now?

Of the 2 analysts covering Lisata Therapeutics, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lisata Therapeutics, Inc. 56 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LSTA?

As at 19 Sept 2026, Lisata Therapeutics, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will LSTA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +135.3% from the last close, and Ticker Nerd's factor model ranks Lisata Therapeutics, Inc. 56 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LSTA stock forecast for 2030?

No analyst covering Lisata Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LSTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has LSTA stock performed over the past year?

Lisata Therapeutics, Inc. returned -28.9% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lisata Therapeutics, Inc. do?

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other major diseases.

What is the latest news on LSTA?

The most recent item we track (Benzinga, 17 Sept 2026): "Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy". Lisata Therapeutics announced it has acquired clinical-stage biotechnology company Marea Therapeutics, alongside an oversubscribed $225 million private placement financing. The moves are aimed at bolstering its cardioendocrine pipeline strategy.

Company

About Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other major diseases. The company’s lead product candidate, certepetide, is designed to activate a novel uptake pathway that may improve the delivery and penetration of anti-cancer drugs within solid tumors. Lisata Therapeutics’ current work centers on oncology programs that evaluate certepetide in combination with existing cancer regimens across several solid tumor settings. The company also maintains research efforts in other disease areas through its broader development pipeline. Headquartered in Basking Ridge, New Jersey, Lisata Therapeutics plays a role in the biopharmaceutical market by advancing treatment approaches intended to enhance how established therapies reach tumor tissue.

CEO Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. · 21 employees · United States · https://www.lisata.com